Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 16, 2022; 10(29): 10701-10707
Published online Oct 16, 2022. doi: 10.12998/wjcc.v10.i29.10701
Immune checkpoint inhibitor-associated arthritis in advanced pulmonary adenocarcinoma: A case report
Yan Yang, Xiao-Jie Huang
Yan Yang, Xiao-Jie Huang, Department of Respiratory Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang Province, China
Author contributions: Yang Y designed the study, interpreted the data, and drafted the paper; Huang XJ participated in clinical treatment and revised the manuscript; both authors approved the final version to be published.
Informed consent statement: Informed written consent was obtained from the patient for the publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Yan Yang, MM, Associate Chief Physician, Department of Respiratory Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou 310000, Zhejiang Province, China.
Received: May 10, 2022
Peer-review started: May 10, 2022
First decision: June 27, 2022
Revised: July 16, 2022
Accepted: September 1, 2022
Article in press: September 1, 2022
Published online: October 16, 2022
Core Tip

Core Tip: We report a severe case of immune checkpoint inhibitor-associated arthritis (IA) in advanced pulmonary adenocarcinoma. A recent study suggested that higher checkpoint inhibitor arthritis disease activity may be associated with cancer progression. In our case, Clinical Disease Activity Index (CDAI) score increased to as high as 43, but cancer disease remained in complete remission 20 mo after the development of IA. Whether CDAI can be a predictor of disease progression needs to be confirmed in future studies.